Amarantus Bioscience has posted a White Paper exploring the company’s LymPro Alzheimer’s Disease diagnostic, prepared by a member of the company’s Board of Advisors. The Paper discusses the increasing prevalence of Alzheimer’s disease, the clinical and economic advantages of early detection, and why the LymPro Test is poised to potentially become the market leading diagnostic product in the Alzheimer’s space.
On March 12, 2013, Acadia Pharmaceuticals (ACAD) reported financial results for the fourth quarter and full year 2012. Total revenues in the quarter were $0.4 million, essentially in-line with our estimate of $0.3 million. Revenues consisted of collaborative payments from Allergan, Inc. (AGN) and other collaboration partners. For the full year 2012, total revenues were $4.9 million.
Amarantus BioSciences, Inc. (AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.
The following is a news release published October 25 by Amarantus BioSciences discussing positive behavioural efficacy data for MANF, the company’s powerful therapeutic protein with neuron-protective properties. Data from a neurorestoration 6-hydroxydopamine (6-OHDA) rat model Parkinson’s disease shows superiority of MANF over GDNF.
OneMedPlace introduces a new series, “The Briefing Room”, capturing the past week’s most important developments in microcap life sciences indexes. This week, we feature Star Scientific, Kips Bay Medical, XOMA and Stellar Pharmaceuticals.
China Analyst, a financial information website focused on U.S.-listed Chinese stocks, recently released its list of the top 10 pharmaceutical stocks with the highest upside.
NWL seeks to prevent degeneration and restore function in damaged tissue, particularly in the nervous system.
Sunnyville, Calif.-based Amarantus Therapeutics is developing therapies to reverse the process of apoptosis.
Pico-Tesla Magnetic Therapies, an emerging medical technology company based in Littleton, CO, has commenced a pilot study of its Magneceutical™ Therapy as a treatment for type 2 diabetes, the most common form of the disease.
Acadia and its partner Biovail made news last month with a failed late-stage trial of pimavanserin, their experimental drug candidate to treat psychosis related to Parkinson’s disease.
Copyright © 2024 | WordPress Theme by MH Themes